BioLineRx Company Profile (NASDAQ:BLRX)

Analyst Ratings

Consensus Ratings for BioLineRx (NASDAQ:BLRX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.25 (437.97% upside)

Analysts' Ratings History for BioLineRx (NASDAQ:BLRX)
Show:
DateFirmActionRatingPrice TargetActions
5/18/2016Roth CapitalReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for BioLineRx (NASDAQ:BLRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.17)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q213($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioLineRx (NASDAQ:BLRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.07)($0.07)($0.07)
Q3 20161($0.07)($0.07)($0.07)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioLineRx (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioLineRx (NASDAQ:BLRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for BioLineRx (NASDAQ:BLRX)
DateHeadline
07/16/16 02:49 PMBiolinerx Limited Ads (NASDAQ:BLRX) Short Interest Decreased By 42.65% - Consumer Eagle
07/15/16 01:29 PMBiolinerx Limited Ads (NASDAQ:BLRX) Shorts Decreased by 42.65% After Short Covering - Press Telegraph
07/15/16 01:29 PMAnalyst Target and Average Rating Watch: BioLineRx Ltd. (NASDAQ:BLRX) - Press Telegraph
07/13/16 02:53 PMBioLineRx Ltd. (NASDAQ:BLRX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/10/16 02:48 PMBioLineRx Ltd. (BLRX) Broker Price Targets For The Coming Week - Fiscal Standard
07/10/16 02:48 PMBioLineRx Ltd. (BLRX) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 02:44 PMCan BioLineRx Ltd. (NASDAQ:BLRX) Improve on the Earnings Front? - Engelwood Daily
07/09/16 02:44 PMCompany Stock Focus for BioLineRx Ltd. (NASDAQ:BLRX): Which Way Will Shares Head? - Press Telegraph
07/06/16 08:40 PMBioLineRx Ltd. (NASDAQ:BLRX) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/04/16 02:49 PMBroker Outlook For The Week Ahead BioLineRx Ltd. (BLRX) - Fiscal Standard
07/01/16 10:55 AMBioLineRx Ltd. (BLRX) Current Analyst Ratings - Fiscal Standard
07/01/16 10:55 AMNew Broker Ratings For BioLineRx Ltd. (BLRX) - FTSE News
06/29/16 07:57 PMBioLineRx Ltd. (NASDAQ:BLRX) Company Rating and Target Watch - Telanagana Press
06/29/16 07:57 PMBiolinerx Limited Ads (NASDAQ:BLRX) Shorts Decreased by 42.65% After Short Covering - Engelwood Daily
06/28/16 03:05 PMStock Update (NASDAQ:BLRX): Bioline RX Ltd Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in ... - Smarter Analyst
06/28/16 07:20 AMBioLineRx (BLRX) Submits Regulatory Filings Needed to Commence BL-8040 Combo Phase 2a in Pancreatic Cancer - StreetInsider.com
06/28/16 06:15 AM7:15 am BioLineRx announces the filing of regulatory submissions required to commence a Phase 2a trial for BL-8040 in combination with KEYTRUDA for the treatment of patients with pancreatic cancer -
06/28/16 06:00 AMBioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer - [PR Newswire] - TEL AVIV, Israel, June 28, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2a trial for BL-8040 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with pancreatic cancer. The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in up to 30 subjects with metastatic pancreatic adenocarcinoma. In January 2016, BioLineRx entered into a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA in patients with metastatic pancreatic cancer.
06/27/16 07:32 AMShare Update and Earnings Review for BioLineRx Ltd. (NASDAQ:BLRX) - Press Telegraph
06/26/16 02:42 PMHow Many Bioline RX Ltd (NASDAQ:BLRX)'s Analysts Are Bullish? - Engelwood Daily
06/24/16 02:52 PMBioLineRx Ltd. (NASDAQ:BLRX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:28 AMCovering the Bases on BioLineRx Ltd. (NASDAQ:BLRX): Where is the Stock Going? - Press Telegraph
06/22/16 08:05 PMBioLineRx Ltd. (BLRX) Updated Price Targets - FTSE News
06/21/16 02:47 PMBrokers Issue Average Price Target Of 4.50 On BioLineRx Ltd. (BLRX) - Fiscal Standard
06/17/16 02:47 PMBioLineRx, Ltd. (NASDAQ:BLRX) decreased -2.09%: Verizon Communications Inc. (NYSE:VZ), United Continental ... - KC Register
06/15/16 06:19 AMBioLineRx to Present at the JMP Securities Life Sciences Conference in New York - [at noodls] - TEL AVIV, Israel, June 15, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
06/03/16 08:57 PMInvestment Analysts' Weekly Ratings Changes for Bioline RX (BLRX) - Let Me Know About This
06/03/16 08:56 PMBioLineRx Ltd. (BLRX) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/03/16 11:26 AMShare Rating Focus on BioLineRx Ltd. (NASDAQ:BLRX) - HNN
06/02/16 02:59 PMOne Small Step for Bioline RX (BLRX) is Actually One Big Step - SmallCap Network - SmallCap NetworkOne Small Step for Bioline RX (BLRX) is Actually One Big StepSmallCap NetworkIt's subtle, but sometimes the best, most productive hints are the simplest, almost-imperceptible ones. Bioline RX Ltd (NASDAQ:BLRX) is pushing up and off of a fairly well-established support level around $0.89. The chart of BLRX below tells the story.
06/02/16 11:37 AMTarget Price and Stock Performance Rundown for BioLineRx Ltd. (NASDAQ:BLRX) - HNN - Target Price and Stock Performance Rundown for BioLineRx Ltd. (NASDAQ:BLRX)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, BioLineRx Ltd. (NASDAQ:BLRX ...and more »
05/27/16 12:18 AMStock Rating Review for BioLineRx Ltd. (NASDAQ:BLRX) - Wall Street Hints and News - Stock Rating Review for BioLineRx Ltd. (NASDAQ:BLRX)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of BioLineRx Ltd. (NASDAQ:BLRX). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »
05/26/16 07:10 PMTarget Check and Stock Performance Recap BioLineRx Ltd. (NASDAQ:BLRX) - Wall Street Hints and News - Target Check and Stock Performance Recap BioLineRx Ltd. (NASDAQ:BLRX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, BioLineRx Ltd.and more »
05/26/16 12:08 AMIs Bioline RX Ltd a Sell? The Stock Formed Multiple Bottom Chart Pattern - Wall Street Hints and News - Is Bioline RX Ltd a Sell? The Stock Formed Multiple Bottom Chart PatternWall Street Hints and NewsThe stock of Bioline RX Ltd (BLRX) shows a multiple bottoms pattern with $0.85 target or 11.00% below today's $0.95 share price. The 9 months chart pattern indicates high risk for the $53.60M company. It was reported on May, 25 by Finviz.com. If the $0 ...
05/22/16 11:42 AMRevenue Update on Bioline RX Ltd(NASDAQ:BLRX) - Trade Calls - Revenue Update on Bioline RX Ltd(NASDAQ:BLRX)Trade CallsBioline RX Ltd(NASDAQ:BLRX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 17, 2016. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.08. In a different note, On Mar 9, ...and more »
05/21/16 06:29 PMAnalyst Rating Check on BioLineRx Ltd. (NASDAQ:BLRX) - Wall Street Hints and News - Analyst Rating Check on BioLineRx Ltd. (NASDAQ:BLRX)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1 on shares of BioLineRx Ltd. (NASDAQ:BLRX). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research. This consensus ...and more »
05/19/16 06:22 AMBioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences - [at noodls] - TEL AVIV, Israel, May 19, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will ...
05/17/16 11:08 AMStock Update (NASDAQ:BLRX): Bioline RX Ltd Reports First Quarter 2016 Financial Results - Smarter Analyst - Stock Update (NASDAQ:BLRX): Bioline RX Ltd Reports First Quarter 2016 Financial ResultsSmarter AnalystKinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, “During the first quarter of 2016, we made significant progress in advancing BL-8040, our lead oncology platform. We announced successful results in our Phase 2a study for relapsed and refractory ...BioLineRx Ltd. (NASDAQ:BLRX) To Report EarningsRisers & FallersBioLineRx Reports First Quarter 2016 Financial ResultsPR Newswire (press release)These Companies Report Their Earnings for May 17FxPips.comall 4 news articles »
05/17/16 07:42 AMBioLineRx Reports First Quarter 2016 Financial Results - [at noodls] - TEL AVIV, Israel, May 17, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
05/16/16 06:40 PMStock Update (NASDAQ:BLRX): Bioline RX Ltd and MaRS Innovation Sign Framework Collaboration Agreement - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:BLRX): Bioline RX Ltd and MaRS Innovation Sign Framework Collaboration AgreementSmarter AnalystBioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS ...BioLineRx Strikes Deal to Review Projects Originating From MaRS Innovation Members (NASDAQ:BLRX)Sonoran Weekly ReviewBioLineRx and MaRS Innovation Sign Framework Collaboration AgreementPR Newswire (press release)all 3 news articles »
05/16/16 12:21 PMHow Many Bioline RX Ltd (NASDAQ:BLRX)'s Analysts Are Bullish? - Wall Street Hints and News - How Many Bioline RX Ltd (NASDAQ:BLRX)'s Analysts Are Bullish?Wall Street Hints and NewsOut of 3 analysts covering BioLineRx (NASDAQ:BLRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioLineRx has been the topic of 2 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Below is a list of ...
05/16/16 06:32 AMBioLineRx and MaRS Innovation Sign Framework Collaboration Agreement - [at noodls] - TEL AVIV, Israel, May 16, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
05/14/16 12:25 AMConsensus Rating Review for BioLineRx Ltd. (NASDAQ:BLRX) - Wall Street Hints and News - Consensus Rating Review for BioLineRx Ltd. (NASDAQ:BLRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of BioLineRx Ltd. (NASDAQ:BLRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/11/16 12:30 AMBiolinerx Limited Ads (NASDAQ:BLRX) Shorted Shares Decreased By 28.9% - B.O.D.Y Confidential - Biolinerx Limited Ads (NASDAQ:BLRX) Shorted Shares Decreased By 28.9%B.O.D.Y ConfidentialThe stock of Biolinerx Limited Ads (NASDAQ:BLRX) registered a decrease of 28.9% in short interest. BLRX's total short interest was 399,500 shares in May as published by FINRA. Its down 28.9% from 561,900 shares, reported previously. With 265,800 ...
05/10/16 07:18 AMBioLineRx to Report First Quarter 2016 Results on May 17, 2016 - [at noodls] - TEL AVIV, Israel, May 10, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
05/08/16 08:45 PMBioLineRx Ltd. (BLRX) Broker Price Targets For The Coming Week - Share Trading News - BioLineRx Ltd. (BLRX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of BioLineRx Ltd. (BLRX). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...and more »
05/08/16 08:45 PMBioLineRx Ltd. (NASDAQ:BLRX) Boasts An Average Rating Of 5 - Stocks Daily - BioLineRx Ltd. (NASDAQ:BLRX) Boasts An Average Rating Of 5Stocks DailyAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. BioLineRx Ltd. (NASDAQ:BLRX) ...and more »
05/06/16 07:20 PMAverage Analyst Rating for BioLineRx Ltd. (NASDAQ:BLRX) - B.O.D.Y Confidential - Average Analyst Rating for BioLineRx Ltd. (NASDAQ:BLRX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on BioLineRx Ltd. (NASDAQ:BLRX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 08:45 PMBroker Outlook For BioLineRx Ltd. (BLRX) - Share Trading News - Broker Outlook For BioLineRx Ltd. (BLRX)Share Trading NewsBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 ...
04/04/16 06:27 AMBioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval - [at noodls] - TEL AVIV, Israel, April 4, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel ...

Social

About BioLineRx

BioLineRx logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.79
  • 50 Day Moving Average: $0.82
  • 200 Day Moving Average: $0.96
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $44.57M
  • Beta: 1.79
  • Current Year EPS Consensus Estimate: $-0.28 EPS
  • Next Year EPS Consensus Estimate: $-0.19 EPS
Additional Links:
BioLineRx (NASDAQ:BLRX) Chart for Wednesday, July, 27, 2016